Work

Preclinical study of a new 177Lu-labeled somatostatin receptor antagonist in HT-29 human colorectal cancer cells.

Year: 2020

Type: article

Abstract: OBJECTIVES: Lu-DOTA-Peptide 2) as a new radioantagonist in HT-29 human colorectal cancer in vitro and in vivo. METHODS: Lu. In vitro assays (saturation binding assay and internalization test) and animal biodistribution were performed in human colon adenocarcinoma cells (HT-29) and HT-29 tumor-bearing nude mice. RESULTS: Lu-DOTA-Peptide 2 to somatostatin receptors. CONCLUSION: Lu-DOTA-Peptide 2 demonstrated selective and high binding affinity to somatostatin receptors overexpressed on the surface of HT-29 cancer cells, which could make this radiopeptide suitable for somatostatin receptor-targeted radionuclide therapy.

Source: PubMed

DOI: 10.22038/aojnmb.2020.44432.1299

Authors: Hossein Behnammanesh, Mostafa Erfani, Maliheh Hajiramezanali, Safura Jokar, Parham Geramifar, Omid Sabzevari, Mohsen Amini, Seyed Mohammad Mazidi, Davood Beiki

Institutions: Tehran University of Medical Sciences, Nuclear Science and Technology Research Institute

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W3040907792

FWCI: 0.301

Cites: 32

Cited by: 3

Related to: 10